On December 24, it was reported that, according to documents disclosed by the Hong Kong Stock Exchange on December 24, LuYe Pharmaceutical Investment Co., Ltd. increased its shareholding on December 18 at an average price of HKD 2.2299 per share.$LUYE PHARMA (02186.HK)$2 million ordinary shares were acquired, valued at approximately HKD 4.4598 million. After the shareholding increase, LuYe Pharmaceutical Investment Co., Ltd.'s latest number of shares held is 1.261 billion shares, and the good warehouse ratio has risen from 33.47% to 33.53%.
This Trade involves Other related parties: Shorea LBG, Ginkgo (PTC) Limited, Luye Life Sciences Group Ltd, LuYe Pharmaceutical International Co., Ltd., LuYe Pharma Holdings Ltd., Nelumbo Investments Limited, and Liu Dianbo.
What is equity disclosure?
According to the requirements of the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) must disclose their shareholding interests in listed companies. The Directors and senior executives of listed companies must disclose their share and debenture interests in both the listed company and its affiliated companies.
Why is equity disclosure important?
Equity disclosure enables investors to identify (1) individuals who control or have the ability to control the shareholding of the listed company and (2) individuals who may benefit from transactions involving entities related to the listed company.